Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

batoprotafib (TNO155)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

PTPN11 inhibitor

Related drugs:

KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D
HER-2 overexpression + KRAS G12C	Non Small Cell Lung Cancer	HER-2 overexpression + KRAS G12C	Non Small Cell Lung Cancer	sotorasib + TNO155 Sensitive: D – Preclinical sotorasib + TNO155 Sensitive : D	sotorasib + TNO155 Sensitive: D – Preclinical sotorasib + TNO155 Sensitive : D
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	crizotinib + TNO155 Sensitive: D – Preclinical crizotinib + TNO155 Sensitive : D	crizotinib + TNO155 Sensitive: D – Preclinical crizotinib + TNO155 Sensitive : D
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	ceritinib + TNO155 Sensitive: D – Preclinical ceritinib + TNO155 Sensitive : D	ceritinib + TNO155 Sensitive: D – Preclinical ceritinib + TNO155 Sensitive : D
ALK mutation	Neuroblastoma	ALK mutation	Neuroblastoma	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D	lorlatinib + TNO155 Sensitive: D – Preclinical lorlatinib + TNO155 Sensitive : D